FINWIRES · TerminalLIVE
FINWIRES

EU、エネルギー規制の執行を強化、電力規制を巡り加盟国を標的に

By

-- 欧州委員会は水曜日、新たな電力市場改革や再生可能エネルギー規則など、主要なエネルギー関連法規の実施を怠った複数の加盟国に対し、法的措置を強化していると発表した。 欧州委員会は、最新の月例違反報告書の中で、クロアチア、ポーランド、ポルトガルに対し、改正されたEU電力市場設計規則を国内法に完全に移行しなかったとして、理由を付した意見書を送付した。 これらの改革は、電力価格の安定化を図り、変動の激しい化石燃料価格への依存度を低減させるとともに、消費者保護を強化し、契約の選択肢を拡大することを目的としている。 EU加盟国は、2025年1月17日までにこれらの規則を実施することが義務付けられており、一部の規定は2026年半ばまで適用期限が延長されている。 EUは、クロアチア、ポーランド、ポルトガルに対し、2か月以内に回答しなければ、欧州司法裁判所に提訴され、罰金が科される可能性があると述べた。 欧州委員会はまた、EU域内における投資家対国家仲裁を禁止するEU規則に違反したとして、ハンガリーにも理由を付した意見書を送付した。 この件は、ハンガリーの石油・ガス会社MOLグループが仲裁裁定の執行を求め、エネルギー憲章条約に基づき新たな仲裁手続きを開始したことに端を発する。 EUの執行機関は、こうした行為はEU裁判所のコムストロイ判決で明確にされたEU法に違反すると述べた。同判決は加盟国間の紛争を禁じている。ハンガリーは2か月以内に規則を遵守しなければ、EU裁判所に提訴される可能性がある。 一方、欧州委員会は、改正された再生可能エネルギー規則を完全に実施していないとして、ギリシャ、マルタ、ポルトガルを欧州司法裁判所に提訴した。 この法律は、運輸、産業、建築物を含むあらゆる分野で再生可能エネルギーの普及を加速させ、EUの気候目標を支援し、輸入燃料への依存度を低減することを目的としている。 欧州委員会は、これら3カ国は既に2025年に正式な通知と理由付き意見を受け取っていたにもかかわらず、懸念事項に適切に対処しなかったと指摘。現在、財政制裁を求めている。

Related Articles

Research

Research Alert: Chrw Q1: Transformation Drives Margin Expansion And Share Gains

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CHRW delivered mixed Q1 results, with adjusted EPS rising 15.4% Y/Y to $1.35, beating consensus by 10%, while revenue remained flat at $4.0B, missing estimates by $40M. Adjusted operating margin expanded 30bps to 26.6% despite revenue headwinds, with employee headcount declining 12.3% as operational transformation continues generating efficiency gains. The company achieved its 12th consecutive quarter of market share gains in NAST, with volumes flat versus a 6.2% decline in the Cass Freight Shipment Index, demonstrating competitive positioning advantages. Management's disciplined cost management approach reduced operating expenses 2.3% to $484.8M, while returning $359.8M to shareholders through buybacks and dividends. We view the challenging freight market environment as an opportunity for CHRW to outperform, as persistent weakness in freight volumes and volatile spot costs create difficulties for peers while CHRW's transformation positions it to gain share in this difficult environment.

$CHRW
Research

Research Alert: Orly: Booming Same-store Sales Growth Drives Q1 Beat And Guidance Raise

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:O'Reilly Automotive (ORLY) posted Q1 EPS of $0.72 vs. $0.62 (+16%), ahead of the $0.70 consensus. The beat was driven by much stronger-than-expected same-store sales (SSS) growth. Net sales rose 10% to $4.56B ($100M ahead of consensus), led by SSS growth of 8.1% (well ahead of the +5.5% consensus), and gross margin expanded 20 bps to 51.5% (10 bps shy of consensus). Notably, ORLY's quarterly SSS growth was the strongest since Q3 2023. ORLY increased full-year EPS guidance to $3.15-$3.25 from $3.10-$3.20, vs. the current consensus of $3.23. Notably, the guidance still assumes total revenue of $18.7B-$19.0B and SSS growth of 3%-5%, despite the company posting an 8.1% growth rate in Q1. ORLY shares are currently trading 6% higher after hours. The company's sizzling SSS growth was the big story. Also, even though the company raised full-year EPS guidance, the sales assumptions in the new guidance appear conservative, potentially setting the stage for another raise later this year.

$ORLY
Research

Research Alert: Align Technology: International Clear Aligner Volumes Support Q1 Sales, Eps Beat

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:ALGN delivered solid Q1 2026 results with revenues of $1.04B, up 6.2% Y/Y, above consensus, while adjusted EPS of $2.58 beat estimates by $0.29. Clear Aligner volumes rose 6.7% to 685.7k cases, with foreign exchange providing a $44.9M tailwind, though underlying constant currency growth was 2.6%. We view broad-based growth across customer segments positively, with orthodontist shipments up 7.4% and GP dentist volumes increasing 5.6%. The company is supported by a strong balance sheet with $1.06B in cash. Management reaffirmed full-year 2026 guidance for 3-4% revenue growth with mid-single digit Clear Aligner volume growth and non-GAAP operating margin of ~23.7%. Adjusted operating margin expanded 240 bps to 21.5%, reflecting restructuring benefits that should continue supporting profitability improvements. The company completed a $200M share repurchase and announced an additional $200M buyback starting May 2026, demonstrating shareholder-friendly capital allocation, in our view.

$ALGN